Drug giant Novo Nordisk just reported some clinical trial data. Despite the seemingly good news, the stock crashed right afterward. There's a difference between a clinical success and a ...

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

Novo Nordisk's Attempt to Overtake Rival Eli Lilly in the Booming Obesity Medicine Market Fails. This Led to the Company's Shares Falling by a Record on Friday. Pritish Nandy, veteran poet and ...

Shares in Novo Nordisk fell yesterday, after it revealed disappointing results from a late-stage trial of its next-generation obesity drug CagriSema, wiping as much as $125bn (€120bn ...

Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of becoming the company’s next blockbuster weight loss drug. RFK Jr. hit an ...

Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados decepcionantes de una de las drogas con las que esperaba superar a su ...

Novo Nordisk (NYSE:NVO)'s new weight loss drug CagriSema missed the company's target of reducing at least 25% body weight of the Phase 3 trials' participants. CagriSema only showed an average 22.7% of ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

The U.S.-listed shares of Novo Nordisk A.S. were plunging toward their worst day in decades on Friday after the results from a late-stage trial showed that the Danish company’s new weight-loss ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker ...